CLL/SLL First-Line Treatments and Second Cancers. What Recent Research Shows
A common concern for people living with CLL/SLL is whether treatment increases the risk of developing another cancer. Recent research offers reassuring news.
What Canadian Experts Are Saying About First-Line, Time-Limited CLL Treatment
What do Canadian hematologists see as the biggest opportunities—and challenges—of time-limited treatment for CLL in previously untreated patients?
New Resource: Navigating Immune Challenges in CLL
If you’re living with CLL, a new resource can help you better understand and manage infection risk. The booklet ‘Navigating Immune Challenges in CLL: Infection Prevention and Management’ provides practical guidance on preventing infections and knowing what to do if one occurs.
Move With Purpose: Small steps to improve energy and wellbeing while living with CLL
Research suggests that gentle movement, even in small amounts, may help people living with CLL improve their energy, reduce symptoms and maintain quality of life. This may be especially true for those who feel the most fatigue or physical limitations.
How a CLL Diagnosis at Age 33 Changed My Life
At 33, I was confronted with two diagnoses that reshaped every assumption I had about my future. I learned I would live with Chronic Lymphocytic Leukemia for the rest of my life, and I was told I would not be able to have biological children.
Looking for a Clinical Trial in Canada? There’s a New Tool to Help
A new Canadian website is making it easier for cancer patients to explore clinical trial options. Search for trials across Canada using simple keywords and filters or get help navigating the site through the Canadian Cancer Society’s Cancer Information Helpline.
CLL Highlights from ASH 2025
In late 2025, the American Society of Hematology (ASH) conference highlighted many important updates for people living with Chronic Lymphocytic Leukemia (CLL), including emerging treatment approaches, long-term follow-up on existing therapies.
A Survey That Really Matters
Calling all patients and care partners to share their experiences to improve patient outcomes. The 2026 Global Patient Survey on Lymphoma & CLL (GPS) is the only opportunity for the worldwide lymphoma and CLL community of patients and care partners to share insights…
Treatment News: Pirtobrutinib; Acalabrutinib + Venetoclax
Pirtobrutinib (brand name Jaypirca) has been approved by Health Canada and is available for use as monotherapy for the treatment of adult patients in Canada with CLL/SLL who have received at least two prior lines of therapy…
When CLL Changes: A Guide for Patients
Richter transformation (RT) is a rare but serious change that can happen in people with chronic lymphocytic leukemia (CLL), where the slower-growing CLL becomes a more aggressive form of lymphoma.